

16-115

Initial Review

BOX AF

RESPONSE UNDER 37 C.F.R. § 1.116° EXPEDITED PROCEDURE

PATENT

EXAMINING GROUP 1205

Attorney Docket No. 61169

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mary R. Flack et al.

Serial No. 08/379,872

Filed: January 27, 1995

For: Gossypol For The Treatment

Of Cancer

Group Art Unit: 1205 \frac{\sqrt{\sq}}}}}}}}}} \signtimes \sqrt{\sq}}}}}}}}}}} \end{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sq}}}}}}}}}} \end{\sqrt{\sqrt{\sqrt{\sq}}}}}}}} \end{\sqrt{\sqnt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sq}}}}}}}}} \end{\sqrt{\sqrt{\sqrt{\sqrt{\sqrt{\sq}}}}}}}}}} \end{\sqrt{\sqrt{\sq}

Examiner: J. Goldberg

RESPONSE TO FINAL OFFICE ACTION

FEB 1 8 1997 GROUP 1200

Assistant Commissioner For Patents Box AF Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action dated September 30, 1996, please consider the following remarks.

REMARKS

The Present Invention

The present invention is directed to a method of treating a cancer in a human wherein the cancer is susceptible to treatment with gossypol, gossypolone or a pharmaceutically acceptable salt thereof. The method comprises administering to the human an anti-cancer effective amount of one of the aforementioned compounds in a pharmaceutically acceptable carrier.